Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Ahammed Hm Mohammed-SadhakathullahInnovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.
Leonor ResinaInnovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.ORCID 0000-0003-4216-8349
Hamidreza EnshaeiInnovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.
Kristina IvanovaGrup de Biotecnologia Molecular i Industrial, Department of Chemical Engineering, Universitat Politècnica de Catalunya, Rambla Sant Nebridi 22, Terrassa 08222, Spain.
Tzanko TzanovGrup de Biotecnologia Molecular i Industrial, Department of Chemical Engineering, Universitat Politècnica de Catalunya, Rambla Sant Nebridi 22, Terrassa 08222, Spain.ORCID 0000-0002-8568-1110
Maria M Pérez-MadrigalInnovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.ORCID 0000-0002-2498-8485
Elaine ArmelinInnovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.ORCID 0000-0002-0658-7696
Juan TorrasInnovation in Materials and Molecular Engineering - Biomaterials for Regenerative Therapies (IMEM-BRT) Group, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya, C/Eduard Maristany 10-14, Building I, second floor, Barcelona 08019, Spain.ORCID 0000-0001-8737-7609
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
A drug delivery platform based on highly porous poly(lactic acid) (PLA) microparticles functionalized with amphiphilic poly(ethylene glycol)-cholesterol (PEG-Chol) has been developed and successfully validated
Indexed as
Antineoplastic AgentsCholesterolNanoparticle Drug Delivery SystemPolyestersBiocompatible MaterialsBreast NeoplasmsCell SurvivalCurcuminDrug CarriersDrug Screening Assays, AntitumorHumansMCF-7 CellsParticle SizePolyethylene GlycolsPorositySurface PropertiesAntineoplastic AgentsBiocompatible MaterialsCholesterolCurcuminDrug CarriersNanoparticle Drug Delivery SystemPolyestersPolyethylene Glycolspoly(lactide)Tamoxifenbreast cancer therapycurcuminpoly(ethylene glycol)−cholesterolpoly(lactic acid) microparticlesTamoxifen
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cholesterol-Functionalized Porous PLA Microparticles for Enhanced Drug Delivery. · full record | OpenQuestion